Slingshot members are tracking this event:

Bristol-Myers Squibb Announces Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 = 5%

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Opdivo, Nivolumab, Advanced Non-small Cell Lung Cancer, Checkmate 026